Biocompatible arsenic trioxide nanoparticles induce cell cycle arrest by p21WAF1/CIP1 expression via epigenetic remodeling in LNCaP and PC3 cell lines

Life Sciences

Volumn 148, Issue , 2016, Pages 41-52

  Jadhav, Vaibhav ^a   Ray, Pritha ^b   Sachdeva, Geetanjali ^c   Bhatt, Purvi ^a  

^a NMIMS UNIVERSITY   (India)

^b CANCER RESEARCH INSTITUTE   (India)

^c NATIONAL INSTITUTE FOR RESEARCH IN REPRODUCTIVE HEALTH   (India)

Author keywords

Arsenic trioxide; Cell cycle arrest; Epigenetic modulations; Nanoparticles; p21WAF1 CIP1; Prostate cancer

Indexed keywords

ARSENIC TRIOXIDE; BIOLOGICAL MARKER; BIOPOLYMER; CASPASE; CHITOSAN; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE H3; LYSINE; NANOPARTICLE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P21; PROTEIN P53; SUCCIMER; ANTINEOPLASTIC AGENT; BIOMATERIAL; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; METAL NANOPARTICLE; ORGANOARSENIC DERIVATIVE; OXIDE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BIOCOMPATIBILITY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL LINE; CELL STRUCTURE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; EPIGENETICS; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LNCAP CELL LINE; M PHASE CELL CYCLE CHECKPOINT; PC3 CELL LINE; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; UPREGULATION; BIOSYNTHESIS; CELL CYCLE CHECKPOINT; DOSE RESPONSE; DRUG EFFECTS; GENETIC EPIGENESIS; MALE; METABOLISM; PHYSIOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ARSENICALS; BIOCOMPATIBLE MATERIALS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENESIS, GENETIC; HUMANS; MALE; METAL NANOPARTICLES; OXIDES; PROSTATIC NEOPLASMS;

EID: 84959016721     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2016.02.042     Document Type: Article

References (66)

1. J. Miki, and J.S. Rhim Prostate cell cultures as in vitro models for the study of normal stem cells and cancer stem cells Prostate Cancer Prostatic Dis. 11 2008 32 39 10.1038/sj.pcan.4501018
2. J.H. Hong, K.S. Ahn, E. Bae, S.S. Jeon, and H.Y. Choi The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo Prostate Cancer Prostatic Dis. 9 2006 147 152 10.1038/sj.pcan.4500856
3. Y. Li, Z. Tian, S.M.A. Rizvi, N.H. Bander, and B.J. Allen In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen Prostate Cancer Prostatic Dis. 5 2002 36 46 10.1038/sj/pcan/4500543
4. C.A. Rothermund, D. Kondrikov, M.F. Lin, and J.K. Vishwanatha Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer Prostate Cancer Prostatic Dis. 5 2002 236 245 10.1038/sj.pcan.4500582
5. J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, and et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in Globocan 2012 Int. J. Cancer 136 2015 E359 E386 10.1002/ijc.29210
6. A.M. DeMarzo, W.G. Nelson, W.B. Isaacs, and J.I. Epstein Pathological and molecular aspects of prostate cancer Lancet 361 2003 955 964 10.1016/S0140-6736(03)12779-1
7. S.K. Sahoo, S. Parveen, and J.J. Panda The present and future of nanotechnology in human health care, nanomedicine nanotechnology Biol. Med. 3 2007 20 31 10.1016/j.nano.2006.11.008
8. G. Pillai Nanomedicines for cancer therapy: an update of FDA approved and those under various stages of development SOJ Pharm. Pharm. Sci. 1-13 2014
9. C.M.J. Hu, S. Aryal, and L. Zhang Nanoparticle-assisted combination therapies for effective cancer treatment Ther. Deliv. 323-334 2010 10.4155/tde.10.13
10. K.B. Sutradhar, and L. Amin Nanotechnology in cancer drug delivery and selective targeting ISRN Nanotechnol. 2014 1 12 10.1155/2014/939378 Review (2014)
11. 4 complex and its anti-tumor effect on hepatocellular carcinoma cells Sensors (Basel) 9 2009 7058 7068 10.3390/s90907058
12. Z. Wang, W. Liu, H. Xu, and X. Yang Preparation and in vitro studies of stealth PEGylated PLGA nanoparticles as carriers for arsenic trioxide Chin. J. Chem. Eng. 15 2007 795 801 10.1016/S1004-9541(08)60005-1
13. 3 complexes combined with magnetic fluid hyperthermia selectively target liver cancer cells World J. Gastroenterol. 15 2009 2995 3002 10.3748/wjg.15.2995
14. T. Kanzawa, L. Zhang, L. Xiao, I.M. Germano, Y. Kondo, and S. Kondo Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3 Oncogene 24 2005 980 991 10.1038/sj.onc.1208095
15. C. Scholz, T. Wieder, L. Stärck, F. Essmann, K. Schulze-Osthoff, B. Dörken, and et al. Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway Oncogene 24 2005 1904 1913 10.1038/sj.onc.1208233
16. C. Scholz, A. Richter, M. Lehmann, K. Schulze-Osthoff, B. Dörken, and P.T. Daniel Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway Oncogene 24 2005 7031 7042 10.1038/sj.onc.1208868
17. L.H. Wei, K.P. Lai, C.A. Chen, C.H. Cheng, Y.J. Huang, C.H. Chou, and et al. Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappaB Oncogene 24 2005 390 398 10.1038/sj.onc.1208192
18. V. Jadhav, S. Sachar, S. Chandra, D. Bahadur, and P. Bhatt Synthesis and characterization of arsenic trioxide nanoparticles and their in vitro cytotoxicity studies on mouse fibroblast and prostate cancer cell lines J. Nanosci. Nanotechnol. 16 2016 1 7 10.1166/jnn.2015.11663 (In Press)
19. A. López-Cruz, C. Barrera, V.L. Calero-DdelC, and C. Rinaldi Water dispersible iron oxide nanoparticles coated with covalently linked chitosan J. Mater. Chem. 19 2009 6870 6876 10.1039/b908777j
20. P.L. Olive, and J.P. Banáth The comet assay: a method to measure DNA damage in individual cells Nat. Protoc. 1 2006 23 29 10.1038/nprot.2006.5
21. B.T. Hughes, J. Sidorova, J. Swanger, R.J. Monnat, and B.E. Clurman Essential role for Cdk2 inhibitory phosphorylation during replication stress revealed by a human Cdk2 knockin mutation PNAS 110 2013 8954 8959 10.1073/pnas.1302927110
22. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the folin phenol reagent J. Biol. Chem. 193 1951 265 275 10.1007/s10982-008-9035-9
23. S. Zhang, L. Chen, T. Liu, B. Zhang, D. Xiang, Z. Wang, and et al. Human umbilical cord matrix stem cells efficiently rescue acute liver failure through paracrine effects rather than hepatic differentiation Tissue Eng. Part A 18 2012 1352 1364 10.1089/ten.TEA.2011.0516
24. L. Bellucci, M. Dalvai, S. Kocanova, F. Moutahir, and K. Bystricky Activation of p21 by HDAC inhibitors requires acetylation of H2A.Z PLoS ONE 8 2013 1 7 10.1371/journal.pone.0054102
25. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients Blood 89 1997 3354 3360
26. C.R. Kumana, W.Y. Au, N.S.L. Lee, M. Kou, R.W.M. Mak, C.W. Lam, and et al. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies Eur. J. Clin. Pharmacol. 58 2002 521 526 10.1007/s00228-002-0514-x
27. Y.L. Lai, H.H. Chang, M.J. Huang, K.H. Chang, W.H. Su, H.W. Chen, and et al. Combined effect of topical arsenic trioxide and radiation therapy on skin-infiltrating lesions of breast cancer-a pilot study Anti-Cancer Drugs 14 2003 825 828 10.1097/01.cad.0000099001.92896.14
28. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins Blood 88 1996 1052 1061
29. J. McCafferty-Grad, N.J. Bahlis, N. Krett, T.M. Aguilar, I. Reis, K.P. Lee, and et al. Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells Mol. Cancer Ther. 2 2003 1155 1164
30. C. Huang, Q. Ke, M. Costa, and X. Shi Molecular mechanisms of arsenic carcinogenesis Mol. Cell. Biochem. 255 2004 57 66 10.1023/B:MCBI.0000007261.04684.78
31. Y.L. Kwong, and D. Todd Delicious poison: arsenic trioxide for the treatment of leukemia Blood 89 1997 3487 3488
32. W.Y. Au, C.R. Kumana, M. Kou, R. Mak, G.C.F. Chan, A. Ching-Wan Lam, and et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia Blood 102 2003 407 408
33. X. Xu, X. Gao, L. Jin, P.S. Bhadury, K. Yuan, D. Hu, and et al. Antiproliferation and cell apoptosis inducing bioactivities of constituents from Dysosma versipellis in PC3 and Bcap-37 cell lines Cell Div. 6 2011 14 10.1186/1747-1028-6-14
34. S. Ramachandran, N. Rajendra Prasad, and S. Karthikeyan Sesamol inhibits UVB-induced ROS generation and subsequent oxidative damage in cultured human skin dermal fibroblasts Arch. Dermatol. Res. 302 2010 733 744 10.1007/s00403-010-1072-1
35. S.R. Samarakoon, I. Thabrew, P.B. Galhena, and K.H. Tennekoon Modulation of apoptosis in human hepatocellular carcinoma (HepG2 cells) by a standardized herbal decoction of Nigella sativa seeds, hemidesmus indicus roots and smilax glabra rhizomes with anti- hepatocarcinogenic effects BMC Complement. Altern. Med. 12 2012 1 9 10.1186/1472-6882-12-25
36. J. Ma, F. Huang, H. Lin, and X. Wang Isolation and purification of a peptide from bullacta exarata and its impaction of apoptosis on prostate cancer cell Mar. Drugs. 11 2013 266 273 10.3390/md11010266
37. S. Alarifi, D. Ali, S. Alkahtani, M.A. Siddiqui, and B.A. Ali Arsenic trioxide-mediated oxidative stress and genotoxicity in human hepatocellular carcinoma cells Onco. Targets. Ther. 6 2013 75 84 10.2147/OTT.S38227
38. O. Garcia, I. Romero, J.E. González, and T. Mandina Measurements of DNA damage on silver stained comets using free internet software Mutat. Res. 627 2007 186 190 10.1016/j.mrgentox.2006.11.007
39. T. Godard, E. Deslandes, P. Lebailly, C. Vigreux, F. Sichel, J.M. Poul, and et al. Early detection of staurosporine-induced apoptosis by comet and annexin V assays Histochem. Cell Biol. 112 1999 155 161 10.1007/s004180050402
40. 2 Free Radic. Biol. Med. 33 2002 691 702 10.1016/S0891-5849(02)00967-X
41. A.L. Kindzelskii, and H.R. Petty Ultrasensitive detection of hydrogen peroxide-mediated DNA damage after alkaline single cell gel electrophoresis using occultation microscopy and TUNEL labeling Mutat. Res. Fundam. Mol. Mech. Mutagen. 426 1999 11 22 10.1016/S0027-5107(99)00081-0
42. J. Füllgrabe, N. Hajji, and B. Joseph Cracking the death code: apoptosis-related histone modifications Cell Death Differ. 17 2010 1238 1243 10.1038/cdd.2010.58
43. WAF1 expression and gene-associated histone acetylation PNAS 97 2000 10014 10019 10.1073/pnas.180316197
44. M.R. Duan, and M.J. Smerdon Histone H3 lysine 14 (H3K14) acetylation facilitates DNA repair in a positioned nucleosome by stabilizing the binding of the chromatin remodeler RSC (remodels structure of chromatin) J. Biol. Chem. 289 2014 8353 8363 10.1074/jbc.M113.540732
45. M.F. Cheng, C.H. Lee, K.T. Hsia, G.S. Huang, and H.S. Lee Methylation of histone H3 lysine 27 associated with apoptosis in osteosarcoma cells induced by staurosporine Histol. Histopathol. 24 2009 1105 1111
46. C.H. Park, and K.T. Kim Apoptotic phosphorylation of histone H3 on Ser-10 by protein kinase Cδ PLoS ONE 7 2012 e44307 10.1371/journal.pone.0044307
47. L. Shi, L. Sun, Q. Li, J. Liang, W. Yu, X. Yi, and et al. Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis PNAS 108 2011 7541 7546 10.1073/pnas.1017374108
48. S. Majid, A.A. Dar, V. Shahryari, H. Hirata, A. Ahmad, S. Saini, and et al. Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-cell translocation gene 3 in prostate cancer Cancer 116 2010 66 76 10.1002/cncr.24662
49. P. Cheung, K.G. Tanner, W.L. Cheung, P. Sassone-Corsi, J.M. Denu, and C.D. Allis Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation Mol. Cell 5 2000 905 915 10.1016/S1097-2765(00)80256-7
50. W.S. Lo, R.C. Trievel, J.R. Rojas, L. Duggan, J.Y. Hsu, C.D. Allis, and et al. Phosphorylation of serine 10 in histone H3 is functionally linked in vitro and in vivo to Gcn5-mediated acetylation at lysine 14 Mol. Cell 5 2000 917 926 10.1016/S1097-2765(00)80257-9
51. E. Simboeck, A. Sawicka, G. Zupkovitz, S. Senese, S. Winter, F. Dequiedt, and et al. A phosphorylation switch regulates the transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors J. Biol. Chem. 285 2010 41062 41073 10.1074/jbc.M110.184481
52. J.M. Yun, M.H. Kweon, H. Kwon, J.K. Hwang, and H. Mukhtar Induction of apoptosis and cell cycle arrest by a chalcone panduratin A isolated from Kaempferia pandurata in androgen-independent human prostate cancer cells PC3 and DU145 Carcinogenesis 27 2006 1454 1464 10.1093/carcin/bgi348
53. WAF1/CIP1 pathway Cancer Sci. 97 2006 430 436 10.1111/j.1349-7006.2006.00195.x
54. E. Devarajan, A.A. Sahin, J.S. Chen, R.R. Krishnamurthy, N. Aggarwal, A.-M. Brun, and et al. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance Oncogene 21 2002 8843 8851 10.1038/sj.onc.1206044
55. G. Nestal de Moraes, É. Carvalho, R.C. Maia, and C. Sternberg Immunodetection of caspase-3 by Western blot using glutaraldehyde Anal. Biochem. 415 2011 203 205 10.1016/j.ab.2011.04.032
56. C. Yedjou, P. Tchounwou, J. Jenkins, and R. McMurray Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells J. Hematol. Oncol. 3 2010 1 9 10.1186/1756-8722-3-28
57. M.L. Agarwal, A. Agarwal, W.R. Taylor, and G.R. Stark p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts PNAS 92 1995 8493 8497 10.1073/pnas.92.18.8493
58. S.K. Radhakrishnan, and A.L. Gartel The PPAR-γ agonist pioglitazone post-trancriptionally induces p21 in PC3 prostate cancer but not in other cell lines Cell Cycle 4 2005 575 577 10.4161/cc.4.4.1583
59. I.V. Lebedeva, D. Sarkar, Z.Z. Su, S. Kitada, P. Dent, C.A. Stein, and et al. Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24 Oncogene 22 2003 8758 8773 10.1038/sj.onc.1206891
60. W.J. Placzek, J. Wei, S. Kitada, D. Zhai, J.C. Reed, and M. Pellecchia A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy Cell Death Dis. 1 2010 e40 10.1038/cddis.2010.18
61. T. Honda, S. Kagawa, K.B. Spurgers, B.T. Gjertsen, J.A. Roth, B. Fang, and et al. A recombinant adenovirus expressing wild-type bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity Cancer Biol. Ther. 1 2002 163 167 10.4161/cbt.63
62. S.J. Elliman, B.V. Howley, D.S. Mehta, H.O. Fearnhead, D.M. Kemp, and L.R. Barkley Selective repression of the oncogene cyclin D1 by the tumor suppressor miR-206 in cancers Oncogenesis 3 2014 e113 10.1038/oncsis.2014.26
63. K.M. Kaukoniemi, H.E. Rauhala, M. Scaravilli, L. Latonen, M. Annala, R.L. Vessella, and et al. Epigenetically altered miR-193b targets cyclin D1 in prostate cancer Cancer Med. 4 2015 1417 1425 10.1002/cam4.486
64. J.T. Lin, H.Y. Li, N.S. Chang, C.H. Lin, Y.C. Chen, and P.J. Lu WWOX suppresses prostate cancer cell progression through cyclin D1-mediated cell cycle arrest in the G1 phase Cell Cycle 14 2015 408 416 10.4161/15384101.2014.977103
65. J. Bao, M. He, Y. Liu, Y. Lu, Y. Hong, H. Luo, and et al. AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation Am. J. Cancer Res. 5 2015 1741 1750
66. WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation Prostate Cancer Prostatic Dis. 8 2005 321 326 10.1038/sj.pcan.4500822